Cellectis

Earnings Release • Sep 30, 2014

PRESS RELEASE

Cellectis: First-half 2014 financial results

A successful therapeutic focus A drastic reduction of its operating expenses

As of September 30, available cash stands at €103 million

Paris, September 30, 2014 - Cellectis SA (Alternext: ALCLS.PA), an expert in developing immunotherapies based on engineered allogeneic CART cells (UCART), presents its first-half 2014 consolidated financial statements to June 30, 2014, approved by the Board of Directors at its meeting held on September 29.

• Total operating revenue is €13.8 M (as compared to €6.9 M for the first six months of 2013), i.e. an increase of 100%. Total operating revenue does not include revenue arising from the agreement signed with Pfizer, which will come into effect only from the second half of 2014.
• Operating results are notably improved, with losses limited to €2.1 M (excluding Cellectis AB) as compared to €16.5 M for the first six months of 2013.
• Net results show a loss of €5 M, which is in sharp contrast to the loss recorded for the first half of 2013, which amounted to €18.5 M.
• As at the date of this release, available cash stands at €103 million.

Limited examination procedures have been applied to the summary half-year consolidated accounts to June 30, 2014. The limited examination report is currently being issued.

Group results for the first half of 2014 demonstrate the relevance of the Group's focused therapy strategy and, as a consequence, its structural reorganization undertaken in early 2013.

A successful implementation of its strategy to focus on therapeutics

• Cellectis is a major player in oncology by way of its groundbreaking approach based on CART cells. With 15 years of experience of technological developments at the frontiers of science, Cellectis is able to engineer T cells with TALEN™ and to develop completely new CARs (Chimeric Antigen Receptors).
• Servier and the biopharmaceutical company Pfizer are Cellectis' two exclusive partners in the area of CARTs in oncology. The work of the three companies relates to a set of 33 targets (markers of cancerous cells), of which 6 are for Servier, 15 for Pfizer and 12 for Cellectis.

• For each of the six product candidates potentially developed for Servier, Cellectis could receive more than 105 million euros of milestone payments as well as royalties on the sales of products. Likewise, for each of the product candidates potentially developed in relation to the 15 Pfizer targets, Cellectis could receive more than 145 million euros of milestone payments as well as royalties on the sales of products. In addition, Pfizer is covering all of Cellectis' R&D costs incurred within the scope of its collaboration.

• With 103 million euros of cash at present and on the back of a drastic reduction in its operating costs, the impact of which is starting to be felt in the first half of 2014, Cellectis is in a strong position to face the challenges of the coming years and to complete its transformation to being a market leader in the biopharmaceuticals sector. The company's cash position is likely to improve by October 28, 2014, the closing date for the exercise of the share subscription warrants issued in 2011. The exercise of these share subscription warrants could contribute an additional approximately 20 million euros to the company's cash position in case of exercise of all the warrants.

• The first-in-man clinical study with its first product UCART19 for the treatment of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL), will begin in the second half of 2015. Servier has an exclusive option on this product.
• Cellectis' first proprietary product (outside of partnerships), UCART123 for the treatment of acute myeloid leukemias, should enter into clinical development in the course of 2016.
• Without making any forecasts, Cellectis is optimistic about the offering to the general public of Scéil, dedicated to the storage of induced pluripotent stem (iPS) cells.
• The sale of Cellectis AB marked the final stage of the Company's therapeutic refocusing, while strengthening its high-potential subsidiary Cellectis plant sciences Inc., based in New Brighton in Minnesota.
• In 7 years, by virtue of its Tools and Services business line, Cellectis has put in place the fundamentals for a worldwide reputation in genome engineering and in iPS cells. It is by means of the development of its expertise in research tools that Cellectis has been successful in developing groundbreaking technology both in therapeutics and in biotechnological agriculture. A new page in the history of Cellectis is being written.

Key highlights of the first 9 months of 2014

• On February 17, Cellectis signed a strategic collaboration agreement with Servier to develop and market six product candidates, paying €7.55 M on signature and up to €105 M for each of those product candidates that might be developed.
• On March 24, Cellectis implemented a capital increase of €20.52 M underwritten by sectorspecialist institutional investors based in the United States, in particular to speed up development of its individual (non-collaborative) portfolio of CART Cell products for treating leukemias and solid tumors.
• On March 25, Cellectis received a recommendation from the European Medicines Agency (EMA), in consultation with the European Commission, for the Cellectis UCART19 product candidate in the field of adoptive immunotherapy against CD19-expressing leukemias and lymphomas. UCART19 fulfils the definition of an Advanced-Therapy medicinal Product (ATmP) and is thus eligible for Scientific Advices and Assessment from the EMA Committee for Advanced Therapies and a possible European Union centralized marketing authorization.
• On June 5, Cellectis concluded a series of agreements with Life Technologies in connection with applications of TALEN.
• On June 5, Cellectis signed an agreement with Accelera (Nerviano Medical Sciences Group) to perform preclinical studies on its flagship product, UCART19.

• On June 9, the Company announced the signature of an agreement with CELLforCURE, Europe's largest commercial industrial facility manufacturing innovative cell therapies and a subsidiary of the LFB biopharmaceuticals group. This partnership relates to the production of clinical batches from Cellectis allogeneic CART cells, with CELLforCURE being responsible for manufacturing clinical batches of product candidates for Cellectis' UCART range.

• On June 18, Cellectis and Pfizer entered into a global collaboration agreement in the field of oncology to develop immunotherapies based on engineered T cells with Chimeric Antigen Receptors (CAR-T) directed at select targets. This agreement involves an upfront payment of \$80 million and funding to cover research and development costs associated with Pfizerselected targets and the four Cellectis-selected targets within the collaboration. Cellectis could receive development, regulatory and commercial milestone payments of up to €145 million per Pfizer product. Furthermore, Pfizer signed an investment contract to purchase around 10% of Cellectis' capital through a reserved capital increase without preferred subscription right, and the subscription of 2,786,924 newly issued shares at a price of €9.25 per share.

• Furthermore, on August 29, Cellectis sold its Swedish subsidiary, Cellectis AB, to the Japanese company Takara Bio Inc. This operation is a continuation of its focusing on therapeutics reflected in the concentration of its business in the field of oncology.

The restructuring announced in 2013 and strategic refocusing on therapeutics and agro-industrial areas implemented over the last 18 months have significantly reduced Group charges and its cash requirements, thereby markedly enhancing its financial situation and making the Company's structure more agile, efficient and competitive.

For further information, please contact:

Cellectis

Philippe Valachs / Jennifer Moore Tel.: +33 (0)1 81 69 16 00 Email: media@cellectis.com

About Cellectis

Cellectis is a biopharmaceutical company focused on oncology. The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 14 years of expertise in genome engineering - based on its flagship TALEN™ products and meganucleases and pioneering electroporation Pulse Agile technology - to create a new generation of immunotherapies for treating leukemias and solid tumors. Cellectis' adoptive cancer immunotherapy is based on the first allogenic T-cells to express a chimeric antigen receptor (CAR) targeting acute and chronic leukemias. CAR technologies are designed to target surface antigens expressed on cancer cells. These treatments reduce the toxicity associated with current chemotherapeutics and have curative potential. Thanks to its life-science-focused pioneering genome-engineering technologies, the Cellectis Group is creating innovative products in multiple fields and with various target markets. Cellectis is listed on the Alternext market (ticker: ALCLS). To find out more about us, visit our web site: www.cellectis.com

Disclaimer

This press release contains certain forward-looking statements concerning Cellectis and its business. These forward looking statements can be identified by the use of forward looking terminology, including the terms "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "should" or "will", or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Such forward-looking statements are based on assumptions that Cellectis considers to be reasonable. However, there can be no assurance that the forecasts or objectives contained in such forward-looking statements will be confirmed or materialized, which forecasts and objectives are subject to numerous risks including the risks set forth in the 2013 financial annual report of Cellectis (a copy of which is available on www.cellectis.com) and to developments in general economic conditions, financial markets and the markets in which Cellectis operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Cellectis or not currently considered material by Cellectis. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Cellectis to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Cellectis shares in any country.

Financial position statement as of June 30, 2014

ASSETS (Euros '000)	June 30, 2014	Dec 31, 2013
Goodwill		1095
Intangilble assets	2 7 7 8	5 5 2 6
Property, plant and equipment	2876	3869
Other non-current assets	538	1 5 1 0
Non-current assets	6 192	12001
Inventories	276	367
Trade and other receivables	12 935	12018
Cash and cash equivalent	20 214	7 5 5 9
Assets held for sale	3 3 3 1
Current assets	36 756	19 9 45
TOTAL ASSETS	42948	31946

LIABILITIES (Euros '000)	June 30, 2014	Dec 31, 2013
Share capital	1 2 5 4	1054
Share premium	152 693	133 244
Reserves	(128801)	(68 232)
Net profit (loss) for the period	(4531)	(61033)
Equity attributable to owners of the company	20616	5032
Non-controlling interests	(666)	(216)
Total equity	19 9 49	4815
Loans and borrowings	2 7 7 0	3 3 7 5
Employees benefits	467	437
Non-current liabilities	3 2 3 8	3812
Loans and borrowings	1 2 3 3	691
Trade and other payables	14 691	20 174
Current provisions	1446	2454
Liabilities held for sale	2 3 9 1
Current liabilities	19761	23 3 19
TOTAL LIABILITIES	42 948	31946

Comprehensive income statement

(Euros '000)	June 30, 2014	June 30, 2013
Revenues	11078	2809
Other operating income	2 7 6 5	4 1 0 0
Total operating income	13843	6909
Cots of licensing-in	(1407)	(960)
Research and development expenses	(5261)	(11068)
Selling General $\&$ Administration expenses	(9418)	(12455)
Other operating income	141	1050
Other operating expenses		(1)
Operating income	(2104)	(16526)
Finance income	161	273
Finance expenses	(145)	(174)
Net finance costs	16	98
Income tax		(1391)
Profit (loss) of ongoing activities	(2088)	(17818)
Profit (loss) of activities held for sale	(2888)
Profit (loss) for the year	(4976)	(17818)
Attributable to owners of the company	(4531)	(17533)
Attributable to minority interests	(445)	(285)
Other elements of comprehensive income:
Exchange rate variances	(17)	(681)
Comprehensive income for the year	(4993)	(18500)
Attributable to owners of the company	(4543)	(18215)
Attributable to minority interests	(450)	(285)
Profit (loss) for the year per share:
- basic earning per share (euros)	(0, 20)	(0, 86)
- diluted earnings per share (euros)	(0, 20)	(0, 86)